Associated Papers
Comparative Analysis of a Dual DNA-RNA Panel and a DNA-Only Panel for Sarcoma: Real-World Data From a Nationwide Genomic Database.
Nakata E et al.
Cancer Science, 2026
Activation of FGFR genes by genetic and epigenetic alterations in uterine leiomyomas.
Jokinen V et al.
Bjc Reports, 2025
Differential Expression of Small Non-Coding RNAs in Uterine Leiomyomas.
Chuang TD et al.
International Journal of Molecular Sciences, 2025
The Effect of Race/Ethnicity and MED12 Mutation on the Expression of Long Non-Coding RNAs in Uterine Leiomyoma and Myometrium.
Chuang TD et al.
International Journal of Molecular Sciences, 2024
Mining cancer genomes for change-of-metabolic-function mutations.
Tu KJ et al.
Communications Biology, 2023
Differential Expression of MED12-Associated Coding RNA Transcripts in Uterine Leiomyomas.
Chuang TD et al.
International Journal of Molecular Sciences, 2023
MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists.
Nagai K et al.
American Journal of Obstetrics and Gynecology, 2023
Are both distinct epithelial and stromal cells molecular analysis from phyllodes tumors versus fibroadenoma components affected in breast fibroepithelial progression?
Waitzberg ÂFL et al.
Acta Cirurgica Brasileira, 2023
Further characterization of tryptophan metabolism and its dysregulation in fibroids.
Chuang TD et al.
F&s Science, 2022
Comparison of MED 12 gene mutation and microRNA-124 expression in leiomyoma and myometrium of Turkish patients.
Demiroglu C et al.
Ginekologia Polska, 2022
Long Noncoding RNA MIAT Modulates the Extracellular Matrix Deposition in Leiomyomas by Sponging MiR-29 Family.
Chuang TD et al.
Endocrinology, 2021
Insights into the regulatory role and clinical relevance of mediator subunit, MED12, in human diseases.
Srivastava S et al.
Journal of Cellular Physiology, 2021
Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.
Cobain EF et al.
Jama Oncology, 2021
Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis.
Hoefflin R et al.
Cancers, 2021
Droplet-digital PCR reveals frequent mutations in TERT promoter region in breast fibroadenomas and phyllodes tumours, irrespective of the presence of MED12 mutations.
Otsuji K et al.
British Journal of Cancer, 2021
Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Williams EA et al.
Acta Neuropathologica Communications, 2020
Ectopic expression of CYP24A1 circular RNA hsa_circ_0060927 in uterine leiomyomas.
Fazeli E et al.
Journal of Clinical Laboratory Analysis, 2020
The genomic mutation spectrums of breast fibroadenomas in Chinese population by whole exome sequencing analysis.
Xie SN et al.
Cancer Medicine, 2019
Mediator Kinase Disruption in MED12-Mutant Uterine Fibroids From Hispanic Women of South Texas.
Park MJ et al.
The Journal of Clinical Endocrinology and Metabolism, 2018
Somatic mutations in benign breast disease tissue and risk of subsequent invasive breast cancer.
Rohan TE et al.
British Journal of Cancer, 2018
Proteomic Profiling of Human Uterine Fibroids Reveals Upregulation of the Extracellular Matrix Protein Periostin.
Jamaluddin MFB et al.
Endocrinology, 2018
Integrative genomic and transcriptomic analysis of leiomyosarcoma.
Chudasama P et al.
Nature Communications, 2018
MED12, TERT promoter and RBM15 mutations in primary and recurrent phyllodes tumours.
Garcia-Dios DA et al.
British Journal of Cancer, 2018
Analysis of MED12 Mutation in Multiple Uterine Leiomyomas in South Korean patients.
Lee M et al.
International Journal of Medical Sciences, 2018
Expanded Somatic Mutation Spectrum of MED12 Gene in Uterine Leiomyomas of Saudi Arabian Women.
Ajabnoor GMA et al.
Frontiers in Genetics, 2018
Genetic analysis of uterine adenosarcomas and phyllodes tumors of the breast.
Geyer FC et al.
Molecular Oncology, 2017
Prevalence and clinical significance of mediator complex subunit 12 mutations in 362 Han Chinese samples with uterine leiomyoma.
Wu J et al.
Oncology Letters, 2017
Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.
Mäkinen N et al.
Molecular Cancer, 2017
Factors affecting the loss of MED12-mutated leiomyoma cells during in vitro growth.
Bloch J et al.
Oncotarget, 2017
Multiple clinical characteristics separate MED12-mutation-positive and -negative uterine leiomyomas.
Heinonen HR et al.
Scientific Reports, 2017
Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays.
Yatsenko SA et al.
Fertility and Sterility, 2017
MED12 mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways.
Laé M et al.
Oncotarget, 2016
MED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas.
Kämpjärvi K et al.
British Journal of Cancer, 2016
Frequency of MED12 mutations in phyllodes tumors: Inverse correlation with histologic grade.
Yoon N et al.
Genes, Chromosomes & Cancer, 2016
Mutational analysis of MED12 exon 2 in a spectrum of fibroepithelial tumours of the breast: implications for pathogenesis and histogenesis.
Lien HC et al.
Histopathology, 2016
Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12.
Mäkinen N et al.
Plos Genetics, 2016
MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast.
Piscuoglio S et al.
Histopathology, 2015
MED12 is frequently mutated in breast phyllodes tumours: a study of 112 cases.
Ng CC et al.
Journal of Clinical Pathology, 2015
MED12 exon 2 mutations in phyllodes tumors of the breast.
Nagasawa S et al.
Cancer Medicine, 2015
Distribution of MED12 mutations in fibroadenomas and phyllodes tumors of the breast--implications for tumor biology and pathological diagnosis.
Pfarr N et al.
Genes, Chromosomes & Cancer, 2015
Mutational analysis of MED12 in fibroadenomas and phyllodes tumors of the breast by means of targeted next-generation sequencing.
Mishima C et al.
Breast Cancer Research and Treatment, 2015
Frequent MED12 mutations in phyllodes tumours of the breast.
Yoshida M et al.
British Journal of Cancer, 2015
Novel MED12 gene somatic mutations in women from the Southern United States with symptomatic uterine fibroids.
Halder SK et al.
Molecular Genetics and Genomics : Mgg, 2015
MED12 mutation frequency in unselected sporadic uterine leiomyomas.
Heinonen HR et al.
Fertility and Sterility, 2014
MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma.
Bertsch E et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2014